Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases

Wiedemann, Andreas; Kaeder, M.; Greulich, W.; Lax, Hildegard; Priebel, J.; Kirschner‐Hermanns, Ruth; Füsgen, Ingo

doi:10.1007/s00345-011-0820-y

Cited by 40 publications

(39 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although Blaivas et al 32 showed that 73% of MS patients without UDS were treated inappropriately, it remains an evaluation tool mainly employed by neurourologists. Wiedemann et al 33 tried to define risk profiling necessitating UDS. EDSS ≥6.5 MS subtypes other than relapsing-remitting and the use of more than one incontinence pad per day were found to increase the likelihood of abnormal UDS findings.…”

Section: Imagingmentioning

confidence: 99%

Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

Aharony¹,

Lam²,

Corcos³

2017

CUAJ

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a unique neurological disease with a broad spectrum of clinical presentations that are time-and disease course-related. MS plaque location (intracranial and/or spinal) is a key feature in the pathophysiology of disease-related lower urinary tract symptoms (LUTS). The prevalence of these symptoms in MS patients is very high, with nearly 90% of them experiencing some degree of voiding dysfunction and/or incontinence. LUTS rarely present as primary MS manifestations and usually appear 6-8 years after the initial diagnosis. Symptom severity usually correlates with the disability status of patients.Patient assessment comprises clinical and advanced investigations. Each patient should be evaluated uniquely, after taking into account his/her symptoms, disease course and length, comorbidities, physical status, and medications. Basic investigation includes detailed history-taking, physical examination, and post-void residual volume measurement. Advanced evaluation consists of imaging and specific testing, with pivotal importance on urodynamic study.

show abstract

Section: Imagingmentioning

confidence: 99%

Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

Aharony¹,

Lam²,

Corcos³

2017

CUAJ

View full text Add to dashboard Cite

show abstract

“…After duplicates removal (n = 100), 147 of 180 screened articles were excluded because they were not related to the neuro-urological follow-up. In all, 23 of 33 full-text articles were included in the quantitative synthesis [1][2][3][4][5][6][7][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. Thus, 10 articles were excluded because they did not bring additional information on the neuro-urological follow-up (six review articles, two case-reports, one animal model, one cross-sectional study) [25][26][27][28][29][30][31][32][33][34].…”

Section: Resultsmentioning

confidence: 99%

“…Most studies were focused on SCI (13 articles), spinal dysraphism (threee articles), and MS (twoarticles). Main results are presented on Table 1 [9][10][11][12][13][14][15][16][17][18][19][20][21].…”

Section: Resultsmentioning

confidence: 99%

“…Ciancio et al [17] 2001 Retrospective cohort 4 22 A significant proportion of patients with MS with and without new urinary symptoms will develop changes in their underlying urodynamic patterns and detrusor compliance during a mean follow-up of 42 months. Wiedemann et al [18] 2013 Cross-sectional 3b 100 UDS showed urinary tract dysfunction in 78% of patients with MS with LUTS. Risk factors for pathological urodynamic findings were wheelchair dependency, use of more than one incontinence pad per day and a MS type other than relapsing-remitting.…”

Section: Reference Publication Year Study Type Le N Most Relevant Resmentioning

confidence: 98%

See 1 more Smart Citation

Follow‐up of the neuro‐urological patient: a systematic review

Averbeck

Madersbacher

2015

BJU International

View full text Add to dashboard Cite

ObjectivesTo systematically review the long-term urological follow-up strategies for patients with neurogenic lower urinary tract dysfunction (NLUTD), focusing on three main groups of neurological diseases: (i) spinal cord injuries, (ii) spinal dysraphism, and (iii) multiple sclerosis. Patients and MethodsData acquisition comprised electronic search on the Medical Literature Analysis and Retrieval System Online (MEDLINE) database and the EMBASE database in August 2014 to retrieve English language studies. MEDLINE and EMBASE search included the following medical subject heading (MeSH) terms: (i) neurogenic bladder and (ii) neurogenic bladder dysfunction. Each of these terms was crossed with (i) long-term care and (ii) long-term surveillance. Only studies related to NLUTD and urological follow-up were included. Studies were also identified by hand search of reference lists and review articles. ResultsInitial records identified through database searching included 265 articles. In all, 23 articles were included in the quantitative synthesis. The proposed time schedule of investigations as well as the amount and type of investigation were different according to specific neurological lesions. They depend on the dysfunctional pattern of the lower urinary tract (LUT) and its risk profile. However, there is a lack of high-evidence level studies to support an optimal long-term follow-up protocol. ConclusionsThe goal of neuro-urological management is the best possible preservation of upper urinary tract (UUT) and LUT function in relation to the individual neurological disorder. Regular and risk adapted controls ('urochecks') allow detection of risk-factors in time before irreversible changes of the LUT and UUT have occurred. With risk-and patient-oriented lifelong regular urological care an optimised quality of life and life-expectancy can be achieved, although there is a complete lack of high-evidence level studies on this topic.

show abstract

“…This suggests that the test does not have to be used as an initial tool in the evaluation of all MS patients or as part of a routine follow-up. UDS still clearly has a role in MS as it accurately diagnoses the dysfunction that is present [54]. The most common urodynamic finding is NDO, reported in as many as 70 %, followed by DSD, in 25 %.…”

Section: Role Of Urodynamicsmentioning

confidence: 97%

Management of Neurogenic Lower Urinary Tract Dysfunction in Multiple Sclerosis Patients

Sadiq

Brucker

2015

Curr Urol Rep

View full text Add to dashboard Cite

Multiple sclerosis (MS) can be a debilitating neurological condition that attributes significant morbidity to bladder dysfunction. Although many effective treatment options exist, symptomatic patients are often underdiagnosed and undertreated. The purpose of this article is to give an overview of the current literature including new screening tools to identify symptomatic patients and updates on treatment options including medications, botulinum toxin, and neuromodulation.

show abstract

Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases

Cited by 40 publications

References 24 publications

Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

Evaluation of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

Follow‐up of the neuro‐urological patient: a systematic review

Management of Neurogenic Lower Urinary Tract Dysfunction in Multiple Sclerosis Patients

Contact Info

Product

Resources

About